Introduction
============

Diastolic dysfunction (DD) is a relatively common cardiac condition and it contributes significantly to the development of heart failure with preserved systolic function in obese patients.[@b1-cmc-7-2013-043] DD is an independent predictor of mortality in patients with normal left ventricular (LV) systolic function;[@b2-cmc-7-2013-043] age, female sex, obesity, hypertension and diabetes mellitus are recognized as predisposing factors for DD.[@b3-cmc-7-2013-043] Overweight/obesity are common conditions encountered in daily medical practice, and it is expected that obesity will become an important cause of heart failure in the coming years.[@b1-cmc-7-2013-043] More importantly, obesity is often associated with other comorbid conditions like diabetes and hypertension, which are known to be independently correlated with DD,[@b4-cmc-7-2013-043] and consequently obesity is infrequently evoked---in daily practice---as an independent determinant of DD. In addition, the pathophysiological development of DD in obesity has not been fully elucidated.[@b5-cmc-7-2013-043]

Whatever the underlying mechanism, the diagnosis of DD is made more difficult by obesity,[@b1-cmc-7-2013-043] and conventional flow Doppler has many limitations for the assessment of DD, given that most parameters are load-dependent.[@b6-cmc-7-2013-043] Conversely, tissue Doppler imaging (TDI) is a useful non-invasive tool providing accurate diagnostic and prognostic values in DD;[@b7-cmc-7-2013-043] furthermore, TDI is relatively load-independent,[@b8-cmc-7-2013-043],[@b9-cmc-7-2013-043] and this issue is of utmost importance in the setting of heart failure when loading parameters are usually disturbed.

The objectives of this study are to analyze the effect of body mass index (BMI) and waist circumference (WC) on LV diastolic function in a community-based population, while also highlighting the value of TDI for the assessment of LVDD in overweight/obese patients.

Methods
=======

Study population
----------------

Between January and June 2012, we evaluated 132 consecutive patients visiting the outpatient echocardiography clinic at a single center in a tertiary university hospital. All patients had a medical record filled, including BMI, heart rate, blood pressure, and WC documentation along with a resting electrocardiogram tracing. Patients were eligible for inclusion if they fulfilled the following criteria: age ≥ 40 years, sinus rhythm, regular medical follow-up, and a signed consent form. Exclusion criteria consisted of: poor sonographic signal, acute medical illness, ejection fraction \< 50%, segmental wall motion abnormalities, restrictive pericarditis, severe valvular disease, pacemaker dependency, bundle branch block, atrioventricular block of any degree, and a sinus rate \> 120 bpm at rest. Demographic data (age, gender, and clinical status) were obtained via detailed history-taking and physical examination. Risk factors and clinical conditions were identified based on self-report of a patient's history, laboratory results, drug use, and/or medical record including previous hospital admissions. A written informed consent was obtained from all study participants and the Institutional Ethical and Research Board approved the study.

Echocardiographic assessment
----------------------------

Echocardiography was performed using the "iE33, Philips" system, and trained sonographers followed a standardized protocol. Conventional diastolic function assessment was performed using an apical view; transmitral flow was sampled by pulsed-wave Doppler at the level of mitral valve leaflet tips; peak velocities of the early phase (E) and late phase (A) of the mitral inflow were measured; then the ratio (E/A) was calculated. TDI was performed to measure myocardial velocities, pulsed sample volume was placed at or 5 mm within the level of the septal mitral valve annulus; early diastolic (E′) and late diastolic (A′) myocardial velocities were recorded; then the ratio E/E′ was calculated. Spectral recording was obtained at a sweep speed of 50 to 100 mm/second at end-expiration, and measurements were averaged over three consecutive cardiac cycles. Special attention is brought to the location of the sample size, as well as gain, filter, and angulations in order to obtain reliable measurements.

Criteria and measurements
-------------------------

Cardiac echogram was performed on a routine basis for cardiac evaluation with or without previously documented cardiac conditions. Regular medical follow- up was defined as presentation for a medical visit at least twice a year for the last 3 years, along with a minimal self-awareness of risk factors, medical conditions, and medication intake. Congestion was considered present when lower leg edema, jugular venous distension, or wet pulmonary rales were documented; exercise intolerance was considered present if fatigue or chest discomfort appeared at minimal to moderate daily activity within the last 6 months; dyspnea was considered present if the patient reported any kind of paroxysmal or persistent breathing difficulty within the last 6 months. Weight and height were measured with participants not wearing shoes and in light clothing.

BMI was calculated as weight (kg) divided by height-squared (m^2^). We divided the study participants into group 1 (control) with normal weight (BMI, 18.5--24.9 kg/m^2^), group 2 with overweight (BMI, 25.0--29.9 kg/m^2^), and group 3 with obesity (BMI, ≥ 30 kg/m^2^), also we used sex-specific cut-offs to define WC as normal (\<102 cm in men and \<88 cm in women).[@b6-cmc-7-2013-043] WC measurements were performed with the patient in a standing position, at the end of an expiratory phase with the tape placed around bare abdomen just above the hip bone. Normal weight obesity was defined as normal BMI (18.5--24.9 kg/m^2^) with an abnormal WC.[@b10-cmc-7-2013-043]

DD was assessed by taking into account the recommendations of the American Society of Echocardiography,[@b11-cmc-7-2013-043] and by accounting for the age of the studied population. DD was considered present when septal E′ was inferior to 7 cm/second; DD was classified as mild (grade 1) when E/A ≤0.7 (impaired relaxation), moderate (grade 2) when E/A \> 0.7 and ≤1.5 (pseudo-normalized pattern), and severe (grade 3) when E/A \> 1.5 (restrictive pattern); increased filling pressure was considered present when E/E′ \> 15.[@b12-cmc-7-2013-043]

Statistical analysis
--------------------

Analysis was performed using the Statistical Package for the Social Sciences software (version 19.0). Data were expressed as the mean ± standard deviation, or the number and percentage as appropriate. Categorical variables were analyzed using the Chi-square test, first comparing all groups then using paired comparisons. Continuous variables were analyzed with Student's *t*-test or analysis of variance followed by post-hoc analysis for multiple comparisons using Tukey's test to assess different subsets as appropriate. Variables found to have significant differences in the univariate analysis were evaluated for multicollinearity and then enrolled into the multivariable logistic regression analysis (stepwise forward logistic regression). A *P*-value \< 0.05 was considered statistically significant.

Results
=======

Clinical characteristics and study subjects
-------------------------------------------

Out of the 132 studied subjects, 99 (mean age 61.59 ± 13.9 years, minimum 45, maximum 92) were eligible; 27 subjects had a normal BMI (group 1), 41 were overweight (group 2), and 31 were obese (group 3). [Table 1](#t1-cmc-7-2013-043){ref-type="table"} shows the clinical characteristics of each group of subjects.

Abnormal BMI (overweight/obesity) was encountered in 72 patients (72.72%), abnormal WC was encountered in nine patients (33.3%) in group 1, 25 patients (61%) in group 2, and 31 patients (100%) in group 3 \[subset paired analysis: WC in group 1 \< WC in group 2 \< WC in group 3, (*P* \< 0.0001)\]. Out of the nine patients with normal weight obesity (group 1), two had LVDD (one impaired relaxation, one pseudonormal pattern). Of note, there was no significant difference between the groups regarding age, gender, heart rate, symptoms, and risk factors, particularly diabetes and hypertension. Moreover, and except for statin therapy, there was no significant difference regarding medication intake between the groups.

Echocardiographic results are shown in [Table 2](#t2-cmc-7-2013-043){ref-type="table"}. Values of LV mass, LV mass index, and septal wall thickness (SWT) were significantly superior in overweight/obese groups compared to values in the normal group \[subset paired analysis, LV mass (group 1 \< group 2 = group 3); LV mass index (group 1 \< group 2 = group 3); SWT (group 1 = group 2 \< group 3)\]. TDI showed a significantly lower E′ in overweight/obese groups compared to the E′ in the normal BMI group (*P* = 0.043). Finally, the E/A ratio and E/E′ratio showed no significant differences; similarly, peak early (E) and late (A) transmitral diastolic flow velocities showed no significant difference among groups, though they were progressively higher from group 1 to group 3.

LVDD was encountered in 75 patients (75.75%), 16 (59.3%) patients from group 1, 32 patients (78.1%) from group 2, and 27 patients (87.1%) from group 3 (*P* = 0.043) ([Table 3](#t3-cmc-7-2013-043){ref-type="table"}). Increased filling pressure was encountered in three (11.11%) patients from group 1, seven (17.07%) patients from group 2, and six (19.35%) patients from group 3.

Impaired relaxation was encountered in eight (29.62%), eleven (26.82%), and eleven (35.48%) patients from groups 1, 2, and 3, respectively. Apseudonormal pattern was encountered in eight (29.62%), 20 (48.78%), and 13 (41.93%) patients from groups 1, 2, and 3, respectively. The restrictive pattern was encountered in none (0%), one (2.43%), and three (9.67%) patients from groups 1, 2, and 3, respectively. [Figure 1](#f1-cmc-7-2013-043){ref-type="fig"} summarizes the LVDD subtype distribution.

Univariate analysis ([Table 4](#t4-cmc-7-2013-043){ref-type="table"}) showed seven variables correlated with LVDD (*P* \< 0.05): age, BMI, WC, LV mass, LV mass index, SWT, and left atrial diameter. In order to identify factors with independent impact on LVDD, multivariate regression analysis was performed and it showed only two variables in the equation: increasing age and abnormal BMI \[OR: 2.75; confidence interval (CI): 1.34--5.67; *P* = 0.006\], ([Table 5](#t5-cmc-7-2013-043){ref-type="table"}).

Discussion
==========

In the present study, increased BMI and age were found to be independent determinants of LVDD. In addition, the prevalence and severity of LVDD was progressively higher from group 1 to group 3. Recent studies showed that increased BMI predisposes an individual to DD, with special highlights on the role of TDI for the assessment of diastolic function in obesity.[@b13-cmc-7-2013-043],[@b14-cmc-7-2013-043] LVDD was encountered in 59.3% of subjects with a normal BMI, and we hypothesize that this finding is related to other associated factors involved in DD, such as aging.

Many substances (angiotensin 2, leptin, resistin, adiponectin ...) are secreted by adipocytes and exert a direct or indirect detrimental effect on the myocardium, and predispose an individual to both LVDD and diastolic heart failure.[@b15-cmc-7-2013-043] In this study, increased filling pressure was more prevalent in group 3; nevertheless, this difference was not statistically significant and we estimate that E/E′ (marker of increased filling pressure) reflects more diastolic heart failure rather than LVDD. Adiponectin deficiency in obesity contributes to myocyte apoptosis, precipitating abnormal relaxation, and can lead to adiposity-related DD.[@b16-cmc-7-2013-043] Similarly, angiotensin 2 and leptin exert a fibrotic effect on the intercellular matrix leading to DD.[@b17-cmc-7-2013-043]

Overweight/obese patients with impaired glucose tolerance show abnormal uptake of calcium by the sarcoplasmic reticulum, leading to prolonged isovolumic relaxation time.[@b18-cmc-7-2013-043] In this study, there was no independent correlation demonstrated between LVDD and diabetes, coronary artery disease, or hypertension. We estimate that disease history (duration, severity, management, and so on) has a significant impact on the potential development of complications like LVDD. This factor was not documented in the study (beyond the design and objective). In addition, patients with these conditions form small subgroups, likely yielding low statistical power.

In this study, abnormal WC was found to be directly correlated with BMI (*P* \< 0.0001) and with LVDD (*P* = 0.035). Nevertheless, WC was not found to be an independent determinant of LVDD, and this is discordant with previously reported data.[@b19-cmc-7-2013-043],[@b20-cmc-7-2013-043] Normal weight obesity (normal BMI, abnormal WC) was encountered in only nine subjects, and only two of them had LVDD. With such a small number, we hypothesize that the statistical power was insufficient to demonstrate an independent impact of normal weight obesity on LVDD. Moreover, in the definition of normal weight obesity, we adopted the criteria "normal BMI with abnormal WC"; fat distribution and concentration were not assessed with markers like waist-to-hip ratio or percentage of body fat.

In the absence of LVDD, left atrial enlargement in overweight/obese subjects correlates with the anthropometric variables and reflects a "physiological" adaptation of the heart to an obese state.[@b21-cmc-7-2013-043] Conversely, in patients with LVDD, left atrial enlargement may be the consequence of chronic LV pressure elevation, and in this case, indexed left atrial volume (\>34 mL/m^2^) is more reliable than indexed left atrial diameter as a marker of LVDD.[@b22-cmc-7-2013-043] In the present study, there was no significant difference in left atrial diameter among the three groups, and we hypothesize---as mentioned above---that the indexed volume is a better marker of left atrial remodeling in this setting.

When LVDD is absent, a mild structural LV remodeling (hypertrophy) in overweight/obese patients may indicate a state of "physiological" adaptation of the heart to obesity, and TDI is crucial in these cases to differentiate "physiological" LV hypertrophy from pathological LV hypertrophy with LVDD.[@b23-cmc-7-2013-043] In the present study, changes in heart structure (LV mass, LV mass index, SWT, and left atrial diameter) were present in the LVDD group; these changes did not show any independent correlation with LVDD in multivariate analysis and we estimate that they are consecutive to increased BMI,[@b22-cmc-7-2013-043],[@b23-cmc-7-2013-043] rather than as a consequence of LVDD. In addition, we hypothesize that significant structural changes occur at the stage of diastolic heart failure with increased filling pressure rather than with LVDD.

Mean heart rate showed no significant difference among the three groups (*P* = 0.591). We hypothesize that this finding is related to the study design (effect of medications, rate \> 120 bpm not included). We also assume that the significant increase in heart rate is a finding in diastolic heart failure rather than LVDD. Similarly, there was no significant difference in dyspnea and exercise intolerance among the groups; we explain this finding by the fact that patients with LVDD are not necessarily at the stage of symptomatic diastolic heart failure. A mild difference in statin therapy among the groups was found (higher in groups 2 and 3; *P* = 0.048). This is a logical finding given that dyslipidemia was more prevalent in these groups, and accordingly more patients are likely taking statins.

Early diastolic annulus/tissue velocity is crucial for the assessment of DD. E′ is not affected by loading factors or by physiological changes like respiration; values of E′ \< 8.5 cm/second at the lateral site and \<8 cm/second at the septal site have been suggested as cut-off values for the diagnosis of LVDD by many authors.[@b11-cmc-7-2013-043] In the present study, we adopted the values used by Russo et al,[@b12-cmc-7-2013-043] who considered that LVDD was present when E′ \< 7 cm/second, taking into consideration the average age of the studied population. Also E and A were used for LVDD subtype classification. E′ is better measured at both levels (septal and lateral averaged).[@b12-cmc-7-2013-043] Nevertheless, many authors adopted only the septal level, and we mentioned this issue as a limitation in this study.[@b24-cmc-7-2013-043]

Kasner et al[@b25-cmc-7-2013-043] did not find any relevant diastolic index or parameter acquired with conventional Doppler echocardiography sufficient enough to make an accurate diagnosis of DD. Early (E) and late (A) diastolic flow velocities, E/A ratio, isovolumic relaxation time, mitral deceleration time, A duration, and pulmonary venous flow correlate weakly with relaxation anomalies and do not allow for an accurate assessment of stiffness or filling pressure. Consequently, the authors concluded that conventional Doppler is of limited value for the detection of DD, and so TDI is more reliable and accurate from this perspective.

Other echographic parameters may have additional value for diastolic function assessment:[@b11-cmc-7-2013-043] diastasis peak velocity, left atrial size, color M-mode flow propagation, Valsalva maneuver, filling time, and color-coded TDI. However, acquiring these additional parameters is time-consuming, color M-mode flow and pulmonary venous flow recording is often technically challenging, and the Valsalva maneuver is not standardized and is often difficult to achieve reliably. In summary, these additional parameters are to be considered on a case-by-case basis when basic TDI is not conclusive, especially in obese patients when echographic signal is poor.

Clinical implications
---------------------

BMI and WC should be assessed more frequently for identifying subjects who are at risk of developing DD and who are likely to benefit from efficient measures like weight reduction or physical rehabilitation.[@b26-cmc-7-2013-043] With weight reduction, there is a reverse of cardiac remodeling that occurs along with improvement in diastolic function.[@b27-cmc-7-2013-043]

TDI can detect asymptomatic LVDD and subsequently help to apply preventive and therapeutic measures early before progression of the condition. Heart failure is a common cardiac condition with poor prognosis despite all of the current management strategies available; accordingly, overweight/obesity (if any) control should be considered a priority in the multifaceted management plan of systolic and diastolic heart failure.[@b28-cmc-7-2013-043] Moreover, an E/E′ ratio \> 15 and an E′ value of \<3 cm/second are markers of poor prognosis; therefore, management must be adapted accordingly.[@b11-cmc-7-2013-043]

The TDI technique is relatively simple to perform. It has been proven to provide an accurate diagnostic and prognostic value in LVDD, and therefore we estimate that its regular use in daily practice is essential.

Limitations
-----------

This study is monocentric and cross-sectional, and the studied population size is limited. E′ was assessed only at the septal annular or basal septal site, although measurement at the lateral and at the septal site (then averaging) is more valuable. We sought to examine an "unselected" group of subjects who would be representative of a broader population; however, most patients in this study were referred for clinically suspected or documented preexisting cardiovascular conditions, and as such they represent a group of patients with a high prevalence of cardiac disease.
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**Abbreviations:** LVDD, left ventricular diastolic dysfunction; Nrl, Normal; IrL, impaired relaxation; PnL, pseudonormal pattern; RtV, restrictive pattern.](cmc-7-2013-043f1){#f1-cmc-7-2013-043}

###### 

Clinical characteristics.

  Parameters             Group 1 (n = 27)   Group 2 (n = 41)   Group 3 (n = 31)   *P*-value
  ---------------------- ------------------ ------------------ ------------------ ---------------------------------------------------------
  Age, y                 62.52 ± 13.91      61.98 ± 13.52      60.26 ± 14.71      0.807
  Male gender            13 (48.1)          26 (63.4)          15 (48.4)          0.329
  Abnormal WC            9 (33.3)           25 (61.0)          31 (100)           \<0.0001[\*](#tfn2-cmc-7-2013-043){ref-type="table-fn"}
  Heart rate, bpm        76 ± 14.97         69.44 ± 11.01      72.84 ± 11.68      0.104
  Exercise intolerance   5 (18.5)           5 (12.2)           4 (12.9)           0.743
  Dyspnea                13 (48.1)          19 (46.3)          16 (51.6)          0.906
  Congestion             3 (11.1)           4 (9.8)            1 (3.2)            0.479
  Coronary artery ds     9 (33.3)           12 (29.3)          7 (22.6)           0.652
  Hypertension           13 (48.1)          20 (48.8)          17 (54.8)          0.843
  Dyslipidemia           4 (14.8)           13 (31.7)          10 (32.3)          0.234
  Diabetes               2 (7.4)            5 (12.2)           3 (9.7)            0.811
  **Medications**                                                                 
  Beta blockers          8 (29.6)           15 (36.6)          16 (51.6)          0.207
  CC blockers            3 (11.1)           5 (12.2)           5 (16.1)           0.830
  ACE-I                  3 (11.1)           6 (14.6)           3 (9.7)            0.801
  Diuretics              4 (14.8)           7 (17.1)           5 (16.1)           0.970
  ARB                    2 (7.4)            1 (2.4)            4 (12.9)           0.229
  Statins                2 (7.4)            12 (29.3)          4 (12.9)           0.048[\*](#tfn2-cmc-7-2013-043){ref-type="table-fn"}

**Notes:** Data are expressed as mean ± standard deviation or counts (percentage).

Significant *P*-value \< 0.05.

**Abbreviations:** y, years; bpm, beats per minute; ds, disease; CC, calcium channel; ACE-I, angiotensin converting enzyme inhibitors; ARB, angiotensin receptor blockers.

###### 

Echo results according to BMI.

  Echo results        Group 1 (n = 27)   Group 2 (n = 41)   Group 3 (n = 31)   *P*-value
  ------------------- ------------------ ------------------ ------------------ ------------------------------------------------------
  LV mass, g          246.88 ± 73.16     310 ± 92.01        329.78 ± 118.97    0.004[\*](#tfn5-cmc-7-2013-043){ref-type="table-fn"}
  LVMI, g/m^2^        144 ± 33.29        178.75 ± 46.54     178.27 ± 52.97     0.005[\*](#tfn5-cmc-7-2013-043){ref-type="table-fn"}
  SWT, mm             13.4 ± 1.91        14.76 ± 2.22       15.11 ± 3.53       0.037[\*](#tfn5-cmc-7-2013-043){ref-type="table-fn"}
  LVEDD, mm           45.85 ± 6.11       45.99 ± 5.15       46.39 ± 5.12       0.923
  Ejection fraction   58.91 ± 9.21       63.55 ± 8.19       62.47 ± 7.02       0.070
  LAD, mm             36.55 ± 4.72       36.95 ± 4.70       38.35 ± 4.52       0.289
  E, cm/s             58.25 ± 16.05      59.86 ± 16.19      60.71 ± 18.83      0.856
  A, cm/s             72.99 ± 19.43      72.44 ± 18.90      71.01 ± 23.52      0.929
  E/A                 0.82 ± 23          0.87 ± 31          0.90 ± 0.34        0.608
  E′, cm/s            6.35 ± 2.43        5.58 ± 1.97        5.03 ± 1.46        0.043[\*](#tfn5-cmc-7-2013-043){ref-type="table-fn"}
  E/E′                10.25 ± 4.17       11.36 ± 2.97       12.35 ± 4.15       0.106

**Note:**

Significant *P*-value \< 0.05.

**Abbreviations:** BMI, body mass index; LVMI, left ventricular mass index; SWT, septal wall thickness; LVEDD, left ventricular end diastolic diameter; LAD, left atrial diameter; E, peak early transmitral diastolic flow velocity; A, peak late transmitral diastolic flow velocity.

###### 

Distribution of diastolic function (normal/abnormal) among groups.

                                Group 1 (n = 27)   Group 2 (n = 41)   Group 3 (n = 31)   *P*-value
  ----------------------------- ------------------ ------------------ ------------------ -----------
  Normal diastolic function     11 (40.7%)         9 (21.9%)          4 (12.9%)          0.043
  Abnormal diastolic function   16 (59.3%)         32 (78.1%)         27 (87.1%)         

**Notes:** Data are expressed as counts (percentage); distribution of normal and abnormal diastolic function among groups.

###### 

Studied variables according to diastolic function results.

  Variables            DD absent (E′ ≥ 7)   DD present (E′ \< 7)   *P*-value
  -------------------- -------------------- ---------------------- ---------------------------------------------------------
  Age, Y               53 ± 12.85           64.33 ± 13.14          \<0.0001[\*](#tfn9-cmc-7-2013-043){ref-type="table-fn"}
  Gender                                                           
   Male                14 (25.9%)           40 (74.1%)             0.847
   Female              10 (22.2%)           35 (77.8%)             
  Abnormal BMI         13 (18.1%)           59 (81.9%)             0.037[\*](#tfn9-cmc-7-2013-043){ref-type="table-fn"}
  Abnormal WC          11 (16.9%)           54 (83.1%)             0.035[\*](#tfn9-cmc-7-2013-043){ref-type="table-fn"}
  Diabetes             1 (10%)              9 (90%)                0.472
  Hypertension         10 (20%)             40 (80%)               0.447
  Coronary artery ds   5 (17.9%)            23 (82.1%)             0.502
  Dyslipidemia         3 (11.1%)            24 (88.9%)             0.109
  Heart rate, bpm      71.08 ± 9.55         72.68 ± 13.42          0.591
  Medications                                                      
   Beta blockers       7 (17.9%)            32 (82.1%)             0.348
   CC blockers         2 (15.4%)            11 (84.6%)             0.651
   ACE-I               1 (8.3%)             11 (91.7%)             0.311
   Diuretics           1 (6.3%)             15 (93.8%)             0.130
   ARB                 3 (42.9%)            4 (57.1%)              0.463
   Statins             2 (11.1%)            16 (88.9%)             0.257
  Echo data                                                        
   LV Mass, g          249.33 ± 76.72       314.87 ± 103.75        0.002[\*](#tfn9-cmc-7-2013-043){ref-type="table-fn"}
   LVMI, g/m2          142.91 ± 32.29       177.51 ± 48.95         0.002[\*](#tfn9-cmc-7-2013-043){ref-type="table-fn"}
   SWT, mm             13.25 ± 1.98         14.9 ± 2.78            0.009[\*](#tfn9-cmc-7-2013-043){ref-type="table-fn"}
   LVEDD, mm           45.72 ± 5.73         46.19 ± 5.28           0.710
   Ejection fraction   64.64 ± 8.92         61.08 ± 7.94           0.067
   LAD, mm             35.58 ± 4.44         37.82 ± 44.63          0.040[\*](#tfn9-cmc-7-2013-043){ref-type="table-fn"}

**Notes:** Data are expressed as the mean ± standard deviationor counts (percentage).

Significant *P*-value \< 0.05.

**Abbreviations:** Y, years; ds, disease; bpm, beats per minute; CC, calcium channel; ACE-I, angiotensin converting enzyme inhibitors; ARB, angiotensin receptor blockers; LVMI, LV mass index; SWT, septal wall thickness; LVEDD, LV end diastolic diameter; LAD, left atrial diameter.

###### 

Multivariate regression analysis.

  Variables   OR     95% CI   *P* value   
  ----------- ------ -------- ----------- ----------
  BMI         2.75   1.34     5.67        0.006
  Age         1.08   1.04     1.12        \<0.0001
  Constant    0.02                        0.002

**Abbreviations:** CI, confidence interval; OR, odds ratio.
